Plain-English translation of NCT05838521 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , which is designed to attack cervical cancer cells by delivering cancer-fighting drugs directly to tumors. The study will enroll about 20 patients with cervical cancer that has come back or continued to grow despite previous chemotherapy. Researchers want to see whether this medication can shrink tumors and help patients live longer.
Cervical cancer that returns or doesn't respond to standard chemotherapy is very difficult to treat, and current options are limited. This medication represents a newer approach—it's designed to be more precise by targeting cancer cells directly while sparing healthy tissue.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication on a schedule: it is given during the first 2 weeks of each 21-day cycle. You will continue receiving the medication as long as it is helping shrink your tumors and you are not experiencing side effects that require stopping treatment. Throughout the study, you will have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Yale University
Collaborators
Gilead Sciences
Enrollment target
~20 participants
Started
June 2023
Primary completion
December 2026
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alessandro D. Santin, MD
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.